In one line
Teratogenic risk is governed by timing, dose, agent and host susceptibility, never by a drug being labelled "unsafe"; the consultant task is to weigh the absolute risk a medicine adds against the often larger risk of leaving the maternal disease untreated, and to counsel with real numbers rather than a letter on a packet.
Mechanism & pathophysiology
Teratogenesis is not random toxicity. Wilson's principles still organise the whole field, and every counselling decision falls out of them.
Timing is the dominant variable. The conceptus passes through windows of differing vulnerability. In the first two weeks (pre-implantation to early implantation) exposure tends to be "all-or-nothing" — a lethal insult causes loss, a survivable one leaves an apparently intact embryo, because the cells are still totipotent and can replace damaged neighbours. Organogenesis (≈ weeks 3–8 post-conception, i.e. ≈ 5–10 weeks' menstrual age) is the critical period for structural malformation: this is when most major teratogens do their damage, and a drug taken only after it has closed (the second and third trimesters) cannot cause the classic malformation even if it is otherwise toxic. Beyond organogenesis the fetus remains vulnerable to functional and growth effects — the brain develops across the whole of pregnancy (hence valproate's neurodevelopmental signal), and the kidney and ductus arteriosus are second/third-trimester targets (ACE-inhibitors, NSAIDs). The single most useful counselling fact is therefore often when the exposure happened relative to organogenesis, not whether it happened.
Dose matters, and most teratogens have a threshold. Below a certain exposure the embryo's repair capacity is not overwhelmed; above it, risk climbs steeply. Valproate is the clean example — major malformation risk rises sharply above roughly 1000 mg/day — and the corollary is that the lowest effective dose of a necessary drug is itself a teratogen-reduction strategy, not a compromise.
Genetic susceptibility decides who is harmed. The same exposure produces a malformed child in one pregnancy and a normal child in another because maternal and fetal genotype modulate the response — variation in folate metabolism, in drug-metabolising enzymes, and in developmental pathways. This is why a teratogen produces a probability, not a certainty, and why a previously affected pregnancy raises the risk for the next.
Mechanism and access complete the picture. Each teratogen acts through a specific molecular pathway: alcohol disrupts Sonic Hedgehog and retinoic-acid signalling and is directly cytotoxic to migrating neural-crest cells, which is why the facial midline and brain are the signature targets; retinoids flood the same retinoic-acid pathway that patterns the pharyngeal arches; folate antagonists (methotrexate, and to a degree valproate and carbamazepine) impair the one-carbon metabolism that closes the neural tube; warfarin inhibits vitamin-K-dependent γ-carboxylation of bone matrix proteins, producing chondrodysplasia punctata. And the agent must reach the embryo — almost all small lipophilic drugs cross the placenta freely, whereas large molecules (heparins, most monoclonal antibodies before the late-pregnancy FcRn-mediated transfer window, insulin) largely do not, which is itself a safety lever.
Against all of this sits the background population risk: roughly 2–3% of all babies have a major congenital malformation with no identifiable cause, and the figure climbs to 4–5% if minor anomalies are counted. No counselling number is interpretable without it. A drug that "doubles the risk" of a 1-in-1000 anomaly still leaves 998 of every 1000 babies unaffected; a drug that adds 8 percentage points to a baseline of 3% is a different conversation entirely. Relative risk frightens; absolute and attributable risk inform. It also bears stating that only a small minority of malformations are drug-attributable at all — most are genetic, chromosomal, multifactorial or unexplained — so a malformation after an exposure is not proof of causation, and counselling must hold both the real risk a teratogen adds and the large background that would have produced anomalies regardless.
The corollary of the timing principle is reversibility. Structural teratogenesis, once organogenesis has miscarried a developmental step, is fixed — the cleft, the neural tube defect or the limb anomaly cannot be undone in utero. Several functional and second/third-trimester effects, by contrast, are reversible if the exposure is withdrawn: the oligohydramnios of an ACE-inhibitor or an NSAID, and the ductal constriction of an NSAID, recover when the drug is stopped. This distinction — fixed structural injury versus reversible functional effect — decides whether an exposure demands detailed counselling and a planned anomaly scan or simply prompt drug withdrawal and surveillance.
The labelling problem — why a letter never answered the question
For decades the FDA letter categories (A, B, C, D, X) were treated as a safety grade, and they were never that. The category reflected the quality and reassurance of the available data, not the magnitude of risk, so two drugs in the same category could carry wildly different real-world hazard, and "no human data" defaulted a drug to category C — which prescribers then read as a mild warning rather than as ignorance. The system actively misled: it implied a hierarchy that did not exist and collapsed the timing/dose nuance that actually governs harm.
The FDA replaced it on 30 June 2015 with the Pregnancy and Lactation Labeling Rule (PLLR), which abolishes the letters and substitutes three narrative subsections — Pregnancy (8.1), Lactation (8.2), and Females and Males of Reproductive Potential (8.3) — each summarising the actual data, the background risk for context, and clinical considerations. The change is conceptual, not cosmetic: it forces the prescriber back to reading the evidence and the timing rather than reaching for a letter. The Australian TGA categories (A, B1–B3, C, D, X) persist and are still seen in SA-adjacent practice, and they carry the same flaw — they conflate evidence quality with risk and must be read with the same scepticism. The practical lesson is that "no data" is not "safe": the commonest counselling error is to reassure on a drug simply because no harm has been demonstrated, when the truth is that it has not been studied.
Assessment — quantifying and communicating risk
The exposed or about-to-be-exposed woman needs the same structured approach whoever she is.
- Establish exactly what, how much, and when. Drug name, dose, route, and the gestational window of exposure mapped against organogenesis. A first-trimester exposure to an agent whose only risk is third-trimester (an NSAID, an ACE-inhibitor) is, on the structural question, reassurable; a second-trimester exposure to a pure first-trimester teratogen has already missed its window of harm. Get the dates right before anything else.
- Use a real teratogen information source, not memory. UKTIS (and its patient-facing arm BUMPS — Best Use of Medicines in Pregnancy), Reprotox/TERIS, and MotherToBaby exist precisely because individual recall of drug-specific risk is unreliable. In SA, the SAMF and the NDoH guidelines anchor what is available and recommended locally; the teratology services anchor the risk figure. Consult them in front of the patient.
- Translate risk honestly. Give the absolute risk ("about 11 in 100, against a background of about 3 in 100") and the attributable risk (the ~8 in 100 added by the drug), not the bare relative risk. State the uncertainty where it exists. And always present the counterfactual: the risk of the untreated maternal disease, which for uncontrolled epilepsy, severe depression, a mechanical heart valve or untreated HIV may dwarf the drug's teratogenic risk.
- Document the discussion. Where a known teratogen has been taken, offer the appropriate detailed anomaly scan (typically the 18–22-week fetal anomaly scan, supplemented where the window allows) and fetal echocardiography where the agent targets the heart (lithium, valproate, retinoids), and record the shared decision — this is medicolegally load-bearing, the consent principles of which are developed in Clinical ethics consent. Where a neural-tube-defect risk applies (valproate, carbamazepine, methotrexate exposure), a careful early scan of the cranium and spine and the option of maternal serum or imaging follow-up belong in the plan.
- Separate the two clocks: the woman who is already pregnant and exposed, and the woman planning pregnancy on a teratogen. The first needs accurate retrospective risk quantification and surveillance; the second needs pre-conception substitution and optimisation, which is where almost all the avoidable harm can be designed out. A chronic-disease drug review is most useful before a positive test, not after — most teratogenic damage from valproate, methotrexate, mycophenolate, warfarin and ACE-inhibitors is preventable only at the planning stage.